Reversal Strategies for VKA: Truths and Misconceptions

Slides:

Advertisements

Similar presentations

Background Methods Results Conclusion Acknowledgements Printed by Multi-Institutional Audit of octaplex® & Comparison with National Recommendations S.

Advertisements

You can never be too Thin…. An Update on NOACs

A Challenging Case of Anticoagulant-Related GI Bleeding

Addressing the Challenges in Primary and Secondary Stroke Prevention

Evaluation of Four Factor Prothrombin Complex Concentrate

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Oral Anticoagulants and Reversal Agents

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Nat. Rev. Cardiol. doi: /nrcardio

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Reversal of Direct Oral Anticoagulants (DOAC)

“Reversing Direct Oral Anticoagulants”

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

AF and PCI in Practice.

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

DOACs and Urgent Bleeding

The Evolving Treatment Landscape in Atopic Dermatitis

What's New in Therapeutic Options for Moderate to Severe RA?

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

NOAC Studies in VTE AF Studies Superior Outcomes.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

Oral Therapies in MS.

NOACs and Reversal Agents

VKA Reversal and LVADs.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.

Perspectives on Revised European Guidelines on Management of Bleeding and Coagulopathy Following Major Trauma.

PCSK9 Inhibitors and Real-World Evidence

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Reversal Strategies for VKA: Truths and Misconceptions

Program Objectives

Typical Indications for Anticoagulation Therapy

The Coagulation Cascade: Pathways and Factors

Coagulation Cascade and Activity Sites of Anticoagulant Therapeutics

Warfarin MoA[a,b]

Pharmacologic Properties of Selected Oral Anticoagulants

Reasons for Urgent Anticoagulation Reversal

Reversal Agents for VKA-Associated Anticoagulation

VKA Therapy Reversal With Vitamin K

FFP for Anticoagulation Reversal

Management of Urgent Anticoagulation Reversal

Volume Overload and Anticoagulation Reversal With FFP

RE-LY Study: Risk of Major Bleeding (% of Patients)

Efficacy and Safety of a 4F-PCC in Patients on VKAs Presenting With Major Bleeding: Key Results From a Phase 3b Study

Outcomes of Urgent Warfarin Reversal With FFP vs 4F-PCC

4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Primary Endpoint Results

4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Adverse Events

Increased Risk of Volume Overload With Plasma Compared With 4F-PCC

Thromboembolic Events Over Time: Plasma vs 4F-PCC

Recombinant FVIIa vs 3F-PCC

Warfarin Reversal by 4F-PCC

Relative Efficacy of Strategies for Reversal of Oral Anticoagulation

Therapeutic Interventions for Reversal of Oral Anticoagulants Based on Urgency[a-e]

What Do Guidelines Recommend?

Updated European Heart Rhythm Association Practical Guide: Management of NOAC-Associated Bleeding

Conclusions

Abbreviations

Abbreviations (cont)